Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 source : Www.athira.com save search
Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
Published: 2021-10-22 (Crawled : 12:00) - athira.com
ATHA | $2.035 -2.63% -2.7% 85K
|
Health Technology
|
| O: 9.45%
H: 9.46%
C: 1.61%
disease alzheimer phase 2 ath-1017 trial enroll alzheimer’s alzheimer's disease alzheimer's
Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2021-09-29 (Crawled : 11:00) - athira.com
ATHA | $2.035 -2.63% -2.7% 85K
|
Health Technology
|
| O: 0.75%
H: 1.17%
C: -0.75%
disease alzheimer phase 2 ath-1017 clinical trials phase 2/3 trials trial conference alzheimer’s alzheimer's disease alzheimer's
Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)
Published: 2021-07-19 (Crawled : 11:00) - athira.com
ATHA | $2.035 -2.63% -2.7% 85K
|
Health Technology
|
| O: -7.12%
H: 9.29%
C: 7.56%
alzheimer phase 1 conference ath-1017 phase 2 phase 3 alzheimer’s alzheimer's
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.